公开(公告)号：US11110185B2

公开(公告)日：2021-09-07

申请号：US15768831

申请日：2016-11-30

申请人： GE Healthcare AS

发明人： Andreas Richard Meijer ,  Mikkel Jacob Thaning ,  Paritosh Jayant Dhawale ,  Salvatore Desena ,  Paul Alexander Jones ,  Deirdre Cassidy ,  Concetta Valeria Gringeri

IPC分类号： A61K49/10

摘要： The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.

公开(公告)号：US20180303960A1

公开(公告)日：2018-10-25

申请号：US15768831

申请日：2016-11-30

申请人： GE Healthcare AS

发明人： Andreas Richard Meijer ,  Mikkel Jacob Thaning ,  Paritosh Jayant Dhawale ,  Salvatore Desena ,  Paul Alexander Jones ,  Deirdre Cassidy ,  Concetta Valeria Gringeri

IPC分类号： A61K49/10

CPC分类号： A61K49/105 ,  A61K49/101 ,  A61K49/108 ,  A61K2123/00

摘要： The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.